Considering that antioxidant signal transduction is a promising therapeutic target in retinopathy diseases, targeting TGF-β1 to promote Nrf2/Keap1/ALDH3A1/HO-1 signaling may be a candidate therapeutic approach for diabetic retinopathy. Here, NFE2L2 is linked to retinal disorder.